Overview

A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers

Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
To demonstrate the bioequivalence of a Olostar Tab versus two co-administered reference IMPs Olmetec and Crestor.
Phase:
Phase 1
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Treatments:
Olmesartan Medoxomil
Rosuvastatin Calcium